Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.
Leukemia and Lymphoma.
Times cited: 5
Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study.
Journal of Clinical Oncology.
Times cited: 394
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
New England Journal of Medicine.
Times cited: 1819